The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects. - sprookjes - yvandenbroek - TriplyDB

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

http://www.wikidata.org/entity/Q37071977

about

Renal drug transporters and their significance in drug-drug interactions Defining a research agenda to address the converging epidemics of tuberculosis and diabetes. Part 1: Epidemiology and clinical management.Acute Care Management of the HIV-Infected Patient: A Report from the HIV Practice and Research Network of the American College of Clinical Pharmacy.Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults.A review of drug-drug interactions in older HIV-infected patients.Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetid The conditional stimulation of rat organic cation transporter 2, but not its human ortholog, by mesoridazine: the possibility of the involvement of the high-affinity binding site of the transporter in the stimulation.Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins.Drug Interactions of Metformin Involving Drug Transporter Proteins.Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.Type 2 diabetes prevalence and its risk factors in HIV: A cross-sectional study.

P2860

Q28071292-6B8EBD75-C5B6-44CE-BBF2-1EF680950DBD Q30234699-F1D5BB45-D424-422C-9A15-3B8C7431F0BA Q38920747-4A6AA58B-E8F7-490E-A755-F6570BE98038 Q40342159-5FB893F4-30AA-4730-962A-878C57965CFA Q41996857-82DE4A55-1795-4D0E-993A-128B4F5E744A Q42099584-8531A935-74F8-4285-AA31-7B3D515B303C Q46320921-2588387C-E3A4-40A7-8360-1173996FFD4C Q47895958-DC2D01A7-400F-4E1D-91A0-515E63073B69 Q49332545-0ACF5BF8-2CC9-43C4-AB9B-BDA347964465 Q53691000-0B058B2C-750B-45C6-986E-45DD2C70F3C4 Q54257862-3D63138E-2A04-4D8C-9371-E6106947241D

P2860

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

http://www.wikidata.org/entity/Q37071977

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

@en

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

@nl

type

label

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

@en

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

@nl

prefLabel

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

@en

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

@nl

P1433

Q37071977-9C6BB542-CCCD-4260-9BC9-13627D509527

P1476

Q37071977-DFC53527-CB91-49C4-8019-48AD13236E50

P2093

Q37071977-265FEE44-160F-4076-9BE8-55C9AF023381

Q37071977-4349C3C9-B55A-4C65-A796-907D5A028F3F

Q37071977-531BE962-DD6D-419A-9E6D-D944F82F69E0

Q37071977-7A5F0A94-58D7-48FD-A0A3-569B81A5573A

Q37071977-7EB99962-6E25-408F-8F6E-32E7FCFC3D43

Q37071977-A4DBBD03-CE6D-4AC6-B7DD-CC6335DBB1B9

Q37071977-C4DFAD0A-5385-4A61-BD95-43EABDE5C347

Q37071977-E33FFA58-932C-41BF-8D86-390B7BBB40B0

Q37071977-EA0E8513-FF2E-407B-8375-B68F4FD77E9F

P2860

Q37071977-0880CE7A-77EF-4A1E-852A-5FC324153E2C

Q37071977-0CBAEF49-D17B-485A-94C0-B113EBA3B955

Q37071977-122C0982-A6FF-49C1-8BD2-7C11E32C6E56

Q37071977-1C20BA9D-0E20-4036-BB6B-1559BDBE3A0C

Q37071977-1FFC1E11-7867-483E-B346-388EB8A35EFB

Q37071977-516B86A8-7CD1-4371-87B3-E4558C1ED37F

Q37071977-61445530-5368-4C3E-871D-52EFFDBEBED2

Q37071977-63CA52F5-A9F3-49F7-82D9-42F330DE38D0

Q37071977-63F3AC56-1DD9-4F5D-A6B4-4DD65C1C8D49

Q37071977-6F36CD7D-09D6-4A5E-AA38-345D879A00C9

P304

Q37071977-A11BF9F8-E050-449E-A101-947A797751EC

P31

Q37071977-2EA34061-8692-4DBF-A1C6-197BF4088BAD

P356

Q37071977-66D525B6-6E55-4EB6-8896-655D1E198548

P407

Q37071977-0DC70882-73B5-4E68-943E-D0B820F4EE0A

P433

Q37071977-63050FCB-5829-4B77-8B77-AF135567CD6B

P478

Q37071977-46BC65A0-F45E-4BFD-837A-1E4A6D694C84

P577

Q37071977-C2457563-1499-4A61-9EC2-5F8AF68E3539

P698

Q37071977-0C238A2A-C206-47EC-9792-1BF233A35126

P921

Q37071977-154F7394-4A2A-4D44-9A49-F80760B1E7DD

P932

Q37071977-E1D72B0D-9A21-4737-9478-3217CA23A867

P356

QAI.0000000000000983

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.

@en

P2093

Brian Wynne

http://www.w3.org/2001/XMLSchema#string

Fred Jerva

http://www.w3.org/2001/XMLSchema#string

Gary D Bowers

http://www.w3.org/2001/XMLSchema#string

Ivy H Song

http://www.w3.org/2001/XMLSchema#string

Jian Zong

http://www.w3.org/2001/XMLSchema#string

Joan E Humphreys

http://www.w3.org/2001/XMLSchema#string

Julie Borland

http://www.w3.org/2001/XMLSchema#string

Maciej J Zamek-Gliszczynski

http://www.w3.org/2001/XMLSchema#string

Mike Choukour

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical Pharmacokinetics of Metformin

Reduction of metformin renal tubular secretion by cimetidine in man

ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Metformin: an old but still the best treatment for type 2 diabetes.

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.

Metformin pathways: pharmacokinetics and pharmacodynamics

P304

400-407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000983

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26974526

http://www.w3.org/2001/XMLSchema#string

P921

P932

4935531

http://www.w3.org/2001/XMLSchema#string